[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 43, "title": "Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hongwei  Wang M.D., Ph.D.", "title": "Head of ADC Development & Clinical Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.07, "open": 1.07, "dayLow": 1.0, "dayHigh": 1.07, "regularMarketPreviousClose": 1.07, "regularMarketOpen": 1.07, "regularMarketDayLow": 1.0, "regularMarketDayHigh": 1.07, "payoutRatio": 0.0, "beta": 1.131, "forwardPE": -0.8907562, "volume": 377727, "regularMarketVolume": 377727, "averageVolume": 498601, "averageVolume10days": 245950, "averageDailyVolume10Day": 245950, "bid": 1.02, "ask": 1.09, "bidSize": 2, "askSize": 2, "marketCap": 65664560, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.1879, "twoHundredDayAverage": 1.61175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -19925476, "profitMargins": 0.0, "floatShares": 41106612, "sharesOutstanding": 61947700, "sharesShort": 4781095, "sharesShortPriorMonth": 6180200, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.077199996, "heldPercentInsiders": 0.23412001, "heldPercentInstitutions": 0.39061, "shortRatio": 6.58, "shortPercentOfFloat": 0.0934, "impliedSharesOutstanding": 61947700, "bookValue": 1.673, "priceToBook": 0.6335923, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -95233000, "trailingEps": -1.61, "forwardEps": -1.19, "enterpriseToEbitda": 0.247, "52WeekChange": -0.6824926, "SandP52WeekChange": 0.19554341, "quoteType": "EQUITY", "currentPrice": 1.06, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.2, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 105432000, "totalCashPerShare": 1.702, "ebitda": -80745000, "totalDebt": 19842000, "quickRatio": 7.306, "currentRatio": 7.753, "totalRevenue": 0, "debtToEquity": 19.245, "revenuePerShare": 0.0, "returnOnAssets": -0.29193002, "returnOnEquity": -0.66305, "grossProfits": 0, "freeCashflow": -28588876, "operatingCashflow": -59497000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1754694525, "regularMarketTime": 1754683200, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.93459, "regularMarketPrice": 1.06, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.06, "postMarketChange": 0.0, "regularMarketChange": -0.0100001, "regularMarketDayRange": "1.0 - 1.07", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 498601, "fiftyTwoWeekLowChange": 0.22699994, "fiftyTwoWeekLowChangePercent": 0.27250892, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.33, "fiftyTwoWeekHighChangePercent": -0.80333954, "fiftyTwoWeekChangePercent": -68.24926, "earningsTimestamp": 1747306800, "earningsTimestampStart": 1755144000, "earningsTimestampEnd": 1755144000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.61, "epsForward": -1.19, "epsCurrentYear": -1.4, "priceEpsCurrentYear": -0.75714284, "fiftyDayAverageChange": -0.1279, "fiftyDayAverageChangePercent": -0.107669, "twoHundredDayAverageChange": -0.55175006, "twoHundredDayAverageChangePercent": -0.3423298, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "cryptoTradeable": false, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-08-09"}]